Original Publication Date: 1 August, 2016
Publication / Source: Hepatic Oncology
Authors: Christopher E Jensen, Arturo Loaiza-Bonilla & Paula A Bonilla-Reyes
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide, and advanced HCC generally caries a poor prognosis. The treatment of advanced disease is limited to sorafenib, which provides only a limited improvement in survival, and novel therapies are, thus, sorely needed. Among emerging alternative approaches, immune checkpoint inhibitors are a particularly promising treatment modality.